Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Chemotherapy in Advanced Esophageal and Gastric Cancer
NCT03469557Phase 2Completed
- Sponsor
- BeiGene
- Start
- Jul 2017
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), Gastric carcinoma (GC), gastroesophageal junction carcinoma (GEJ), sponsored by BeiGene. Started Jul 2017; status: completed.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)Gastric carcinoma (GC)gastroesophageal junction carcinoma (GEJ)
Beyond the preview
Go deeper on NCT03469557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03469557.